Effects of adalimumab, etanercept and ustekinumab on the expression of psoriasin (S100A7) in psoriatic skin.
BACKGROUND
Psoriasis is a chronic inflammatory skin disease. It is characterized by immune cell activation and altered epidermal differentiation. S100A7 (psoriasin) is overexpressed in psoriasis, suggesting a determinant role of this protein in inflammation and keratinocyte differentiation.


OBJECTIVE
The purpose of this study was to investigate the expression of S100A7 in the skin from psoriatic patients undergoing biological therapy with adalimumab, etanercept or ustekinumab.


METHODS
S100A7 expression and distribution were analyzed by immunohistochemistry.


RESULTS
S100A7, overexpressed in epidermal keratinocytes of psoriatic lesions, was downregulated, under the biological therapy with adalimumab, etanercept or ustekinumab, only in patients achieving a PASI score<15.


CONCLUSIONS
Dysregulation of S100A7 may represent a non-negligible player in the maintenance of psoriasis and the relative epidermal changes. Blockage of S100A7 may represent an additional therapeutic approach in the treatment of psoriasis.
Department of Biomedical and Biotechnological Sciences, University of Catania, Italy. Electronic address: f.damico@unict.it.
Fabio
F
D'Amico
Department of Biomedical and Biotechnological Sciences, University of Catania, Italy.
Chiara
C
Trovato
Department of Biomedical and Biotechnological Sciences, University of Catania, Italy.
Evangelia
E
Skarmoutsou
Department of Biomedical and Biotechnological Sciences, University of Catania, Italy.
Giulio A
GA
Rossi
Department of Biomedical and Biotechnological Sciences, University of Catania, Italy.
Mariagrazia
M
Granata
Unità Operativa Complessa di Dermatologia, Azienda Ospedaliera Universitaria Policlinico-Vittorio Emanuele, Catania, Italy.
Valentina
V
Longo
Servizio di Anatomia Patologica, Azienda Ospedaliera Universitaria Policlinico-Vittorio Emanuele, Catania, Italy.
Pietro
P
Gangemi
Unità Operativa Complessa di Dermatologia, Azienda Ospedaliera Universitaria Policlinico-Vittorio Emanuele, Catania, Italy.
Maurizio
M
Pettinato
Department of Biomedical and Biotechnological Sciences, University of Catania, Italy.
Maria Clorinda
MC
Mazzarino
D000068879:Adalimumab / Q000494:pharmacology / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000068800:Etanercept / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000378:metabolism; D000075023:S100 Calcium Binding Protein A7; D009418:S100 Proteins / Q000378:metabolism*; D012867:Skin / Q000187:drug effects / Q000378:metabolism; D000069549:Ustekinumab / Q000494:pharmacology / Q000627:therapeutic use*; D055815:Young Adult
D000075023:S100 Calcium Binding Protein A7; D009418:S100 Proteins; C089242:S100A7 protein, human; D000069549:Ustekinumab; D000068879:Adalimumab; D000068800:Etanercept
Biological therapy; IL-12/-23p40; Psoriasin; Psoriasis; S100A7; TNF